Percutaneous Closure of Patent Ductus Arteriosus.
Clin Perinatol
; 49(1): 149-166, 2022 03.
Article
en En
| MEDLINE
| ID: mdl-35209997
ABSTRACT
Percutaneous-based patent ductus arteriosus closure is technically feasible among infants less than 1.5 kg. However, marked heterogeneity in the type and nature of adverse events obscures current safety profile assessments. Although data on the risks of postdevice closure syndrome remain promising, a lack of comparative trials of surgical ductal ligation and inconsistent surveillance across published studies obscure confidence in present estimates of safety and efficacy. To minimize risk and yield the greatest benefits, clinical studies of patent ductus arteriosus treatment should consider incorporating more robust assessments to ensure that infants at greatest risk for adverse ductal consequences are included.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Conducto Arterioso Permeable
Límite:
Humans
/
Infant
/
Newborn
Idioma:
En
Revista:
Clin Perinatol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos